SiBionics Showcases Innovative Diabetes Management Solutions at EASD 2025

SiBionics CGM + CKM Technology: A Revolutionary Step in Diabetes Care

At the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Vienna, SiBionics unveiled its innovative continuous glucose monitoring (CGM) and continuous ketone monitoring (CKM) integrated solution. This initiative, aiming at better diabetes management, garnered significant interest from leading researchers globally. Under the theme "CGM + CKM for Improved Diabetes Management," the symposium featured prominent scientists who shared the latest scientific evidence paired with SiBionics' innovative approaches, sparking enthusiastic discussions and gaining considerable support for the company's potential to reshape diabetes care practices.

Professors Linong Ji from Peking University and Stefano Genovese from Italy co-chaired the conference, which included distinguished speakers such as Prof. Andrej Janež from Slovenia, Prof. Nina Jendrike from Germany, and Dr. Yifei Mo from China, who presented their most recent research findings. The exhibition area showcased a keen interest in SiBionics’ next-gen devices, including the GS3 glucose monitoring system and KS3 ketone monitoring device. Attendees engaged in conversations about the devices' technical advantages and their clinical relevance for real-world diabetes management.

A critical aspect of the discussion was the feasibility study, confirming that SiBionics’ technologies meet and often exceed the performance standards set by the iCGM criteria across various key efficacy indicators. Renowned for their high precision and clinical reliability, the GS3 system demonstrated exceptional performance, particularly in the context of hypoglycemia, surpassing iCGM requirements and validating its significance in both clinical decision-making and patient self-management of diabetes.

As an emerging leader in glucose monitoring technology and the only company in the world currently commercializing KG systems, SiBionics evidences robust research and development capabilities alongside a visionary approach. Looking ahead, the company plans to continue expanding its CXM portfolio, propelling innovations and delivering accurate, high-quality solutions designed to enhance healthcare outcomes for diabetes patients worldwide.

Founded in 2015, SiBionics, based in Shenzhen and Irvine, stands as a leading medical device manufacturer focused on biosensor innovation. Their integrations of advanced glucose monitoring technology with smart algorithms and user-friendly software aim to improve health management significantly. With a dedicated team of over 500 employees, comprising 25% in research and development, SiBionics is committed to advancing data-driven personalized healthcare.

For more information, interested parties are encouraged to reach out via email at [email protected].

For visuals and logos, please refer to the following links: